Lexicon Pharmaceuticals, Inc. (LXRX)
June 25, 2012 10:00 a.m. ET
Wade Walke - Senior Director, Communications and Investor Relations
Arthur Sands - President and Chief Executive Officer
Brian Zambrowicz - Executive Vice President and Chief Scientific Officer
Pablo Lapuerta - Senior Vice President of Clinical Development and Chief Medical Officer
Jeff Wade - Executive Vice President and Chief Financial Officer
Cory Kasimov - JPMorgan
Alan Carr - Needham & Company
Liana Moussatos - Wedbush Securities
David Friedman - Morgan Stanley
Kevin Kedra - Gabelli & Company
Nicholas Bishop - Cowen and Company
Thank you for holding. Welcome to the Lexicon Pharmaceuticals conference call and webcast to discuss LX4211 top-line Phase 2b study results. At this time all participants are in a listen-only mode. There will be a question-and-answer session to follow. Please be advised that this call is being recorded at Lexicon’s request.
At this time I would like to introduce your host for today's call, Wade Walke, Senior Director of Communications and Investor Relations. Please go ahead, Dr. Walke.
Good morning, and welcome to the Lexicon Pharmaceuticals conference call and webcast. I am Wade Walke and with me today are Dr. Arthur Sands, Lexicon’s President and Chief Executive Officer; Dr. Brian Zambrowicz, Lexicon’s Executive Vice President and Chief Scientific Officer; Dr. Pablo Lapuerta, Lexicon’s Senior Vice President of Clinical Development and Chief Medical Officer.
We expect that you have seen the copy of our press release that was distributed this morning. During this call we will review the information provided in the release, provide further detail on the top line results from the LX4211 Phase 2b study, then use the remainder of our time to answer your questions. If you would like to view the slides for today's call, please access the Lexicon website at www.lexpharma.com, you will see a link on the home page for today's webcast.